U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885267) titled 'Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors' on Oct. 12.
Brief Summary: This is a first-in-human, open-label, multicenter Phase 1 study of AT-0174, an investigational oral dual TDO2/IDO1 inhibitor. It is being conducted in adults with advanced solid tumors that have progressed on, or are not suitable for, standard therapy. The main goals are to evaluate the safety and tolerability of AT-0174 and to identify a recommended dose for further study.
Study Start Date: Nov. 15, 2023
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: AT-0174
Oral capsules taken once daily.
Recr...